Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors
- 297 Downloads
Purpose of Review
Wnt signaling plays a central role in development and homeostasis, and its dysregulation is a common event in many types of human cancer. Here we explore in detail the contributions of Wnt signaling to the initiation and maintenance of three types of saroma: Ewing sarcoma, osteosarcoma, and malignant peripheral nerve sheath tumors. This review provides an overview of the Wnt signaling pathway and explores in detail the current knowledge about its role in the initiation or maintenance of three tumor types: Ewing sarcoma, osteosarcoma, and malignant peripheral nerve sheath tumors.
Recent work has assessed the role(s) of Wnt signaling within these cell types. This review provides an overview of the mechanistic insights that have been gained from a number of recent studies to set the foundation for potential therapeutic applications.
Wnt signaling has emerged as a potentially critical pathway in maintaining the growth of these types of tumors. Given the fact that many new inhibitors of the pathway have recently or will soon enter Phase 1 clinical trials, it is likely that assessment of their activity in these tumor types will occur in human patients.
KeywordsWnt β-catenin Ewing sarcoma Neurofibromatosis Type 1 Osteosarcoma Malignant peripheral nerve sheath tumors
Work in these areas is supported by NIH grants to BOW (AR053293) and PJG (CA188314). MRS is supported by the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research sponsored by Johns Hopkins University’s Neurofibromatosis Therapeutic Acceleration Program (NTAP). PJG has received additional support from Alex’s Lemonade Stand Reach Award and Lily’s Garden Foundation. We thank Nicole Ethen for assistance with preparation of the figure.
Compliance with Ethical Standards
Conflict of Interest
Matthew Pridgeon, Patrick Grohar, and Matthew Steensma declare no conflict of interest.
Bart Williams reports speaker honoraria from Vertex Pharmaceuticals and personal fees as a member of the board of scientific advisor from Surrozen.
Human and Animal Rights and Informed Consent
This article does not contain any studies that include human or animal subjects performed by any of the authors.
BOW has received honoraria from Amgen and Vertex Pharmaceuticals. BOW serves on the Board of Scientific Advisors for, and owns stock inSurrozen.
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
- 4.Hrckulak D, Kolar M, Strnad H, Korinek V. TCF/LEF transcription factors: an update from the internet resources. Cancers (Basel). 2016;8(7).Google Scholar
- 8.Green J, Nusse R, van Amerongen R. The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction. Cold Spring Harb Perspect Biol. 2014;01:6(2).Google Scholar
- 11.Mason JJ, Williams BO. SOST and DKK: antagonists of LRP family signaling as targets for treating bone disease. J Osteoporos. 2010;01:2010.Google Scholar
- 21.Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;01:4(5).Google Scholar
- 22.•• Hao HX, Jiang X, Cong F. Control of Wnt receptor turnover by R-spondin-ZNRF3/RNF43 signaling module and its dysregulation in cancer. Cancers (Basel). 2016;8(6). This review provides an outstanding overview of the recently elucidated genetic changes that increase Wnt receptor availability on the cell surface which may drive tumorigenesis.Google Scholar
- 36.Pizzo PA, Poplack DG. Principles and practice of pediatric oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.Google Scholar
- 40.Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, et al. Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. Oncotarget. 2016.Google Scholar
- 52.•• Pedersen EA, Menon R, Bailey KM, Thomas DG, Van Noord RA, Tran J, et al. Activation of Wnt/beta-Catenin in Ewing sarcoma cells antagonizes EWS/ETS function and promotes phenotypic transition to more metastatic cell states. Cancer Res. 2016;76(17):5040–53. This manuscript presents novel concepts in terms of the relationship between heterogenous activation of Wnt signaling within subpopulations of tumors and disease progression. CrossRefPubMedGoogle Scholar
- 57.von Heyking K, Roth L, Ertl M, Schmidt O, Calzada-Wack J, Neff F, et al. The posterior HOXD locus: Its contribution to phenotype and malignancy of Ewing sarcoma. Oncotarget. 2016;7(27):41767–41780.Google Scholar
- 72.Wei R, Cao G, Deng Z, Su J, Cai L. miR-140-5p attenuates chemotherapeutic drug-induced cell death by regulating autophagy through inositol 1,4,5-trisphosphate kinase 2 (IP3k2) in human osteosarcoma cells. Biosci Rep. 2016;36(5).Google Scholar
- 77.•• Rahrmann EP, Watson AL, Keng VW, Choi K, Moriarity BS, Beckmann DA, et al. Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. Nat Genet. 2013;45(7):756–66. This study helped establish Wnt/B-catenin signaling as a potential tumorigenic driver in NF1.CrossRefPubMedPubMedCentralGoogle Scholar
- 84.Lu B, Green BA, Farr JM, Lopes FC, Van Raay TJ. Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials. Cancers (Basel). 2016;8(9).Google Scholar
- 85.Ahmed K, Shaw HV, Koval A, Katanaev VL. A second WNT for old drugs: drug repositioning against WNT-dependent cancers. Cancers (Basel). 2016;8(7).Google Scholar
- 88.Cadigan KM, Waterman ML. TCF/LEFs and Wnt signaling in the nucleus. Cold Spring Harb Perspect Biol. 2012;01:4(11).Google Scholar